ストックスクリーナーアプリを入手
34.75
3.47%
-1.25
プレマーケット:
34.35
-0.40
-1.15%
前日終値:
$36.00
開ける：
$36.01
24時間の取引高:
375.11K
Relative Volume:
0.97
時価総額：
$1.57B
収益：
-
当期純損益:
$-85.57M
株価収益率:
-18.13
EPS:
-1.9166
ネットキャッシュフロー:
$-72.14M
1週間 パフォーマンス:
+3.15%
1か月 パフォーマンス:
-13.60%
6か月 パフォーマンス:
-18.98%
1年 パフォーマンス:
+142.84%
1日の値動き範囲:
$34.42
$36.20
1週間の範囲:
$32.84
$37.82
52週間の値動き範囲:
$13.51
$48.45
Sionna Therapeutics Inc Stock (SION) Company Profile
名前
Sionna Therapeutics Inc
セクター
電話
617-819-2020
住所
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
34.75 | 1.63B | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Citizens | Mkt Outperform |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-04 | 開始されました | Guggenheim | Buy |
| 2025-03-04 | 開始されました | Stifel | Buy |
| 2025-03-04 | 開始されました | TD Cowen | Buy |
すべてを表示
Sionna Therapeutics Inc (SION) 最新ニュース
SION Q1 2026 Earnings: Wider Loss Surprises as Clinical Progress ContinuesFinal Results - newsline.com
Sionna Therapeutics - The Business Journals
Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price Returns - Yahoo Finance
Transcript : Sionna Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Sionna Therapeutics (SION) Gains 1.81% as Biotech Sentiment ImprovesAdaptive Moving Average - newsline.com
SION Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces Investor SkepticismGrowth Acceleration Report - newsline.com
Biotech Sionna Therapeutics at Jefferies and Goldman Sachs in June - Stock Titan
Sionna Therapeutics director Peter Thompson sells $4,493 of shares - Investing.com India
Sionna Therapeutics director Peter Thompson sells $4,493 of shares By Investing.com - Investing.com South Africa
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock - Investing.com
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock By Investing.com - Investing.com UK
Form 144 | Sionna Therapeutics(SION.US) Insider Proposes to Sell 46.33 Million in Common Stocks - Moomoo
Sionna Therapeutics (SION) Sees Slight Decline Amidst Key Support TestPre-Earnings Momentum - The Legal Advocate
SIONSionna Therapeutics Inc. stock news, filings & ratings - Quantisnow
Sionna Therapeutics (SION) Edges Higher as Biotech Sentiment Improves — Testing Key ResistanceAdvance Decline Volume - thelegaladvocate.com
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences - markets.businessinsider.com
SION Reiterates by Citizens -- Price Target Maintained at $63 - GuruFocus
Stifel Nicolaus Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data - Investing.com
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential By Investing.com - Investing.com Canada
SION Q1 2026 Earnings: Clinical-Stage Biotech Misses Estimates with Wider Net LossEarnings Growth Forecast - newsline.com
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $50 to $63 - Moomoo
Freedom Broker downgrades Sionna Therapeutics (SION) - MSN
Sionna Therapeutics Cut to Hold From Buy by Freedom Broker - Moomoo
SION: Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy - TradingView
Sionna Therapeutics Price Target Maintained With a $38.00/Share by Freedom Broker - Moomoo
Sionna Therapeutics stock rating cut to Hold at Freedom Broker By Investing.com - Investing.com Canada
SION Maintained by Stifel -- Price Target Raised to $55 - GuruFocus
Sionna Therapeutics Price Target Raised to $55.00/Share From $44.00 by Stifel - Moomoo
Wedbush Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Stifel raises Sionna Therapeutics price target on NBD1 data confidence By Investing.com - Investing.com Canada
Sionna Therapeutics (SION) Stock: Slides -0.80%, Support at $37.90 2026-05-18Strangle Setup - newsline.com
User - FinancialContent
Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN
Sionna Therapeutics, Inc. $SION Shares Purchased by Vanguard Group Inc. - MarketBeat
Sionna Therapeutics Develops Next-Generation Cystic Fibrosis Modulators - HarianBasis.co
RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Wedbush Initiates Coverage of Sionna Therapeutics (SION) - Insider Monkey
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout - TipRanks
LifeSci Capital Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Sionna Therapeutics Q1 Net Loss Narrows - Moomoo
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.4% on Disappointing Earnings - MarketBeat
Guggenheim reiterates Sionna Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Sionna stock ahead of summer data - Investing.com
Sionna Therapeutics Inc (SION) 財務データ
収益
当期純利益
現金流量
EPS
Sionna Therapeutics Inc (SION) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
May 27 '26 |
Sale |
44.49 |
101 |
4,493 |
2,671,721 |
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):